title: Supplementation with 80,000 IU vitamin D3/month between November and April corrects vitamin D insufficiency without overdosing: Effect on serum 25-hydroxyvitamin D serum concentrations.
abstract: BACKGROUND
  Vitamin D insufficiency, defined by a 25-hydroxyvitamin D (25OHD) serum concentration<20ng/mL, is highly frequent in the French general population, especially between November and April. The aim of this study was to evaluate whether 80,000 IU vitamin D3 every month during this period of the year was able to maintain a 25OHD level between 20 and 60ng/mL in apparently healthy subjects whatever their basal vitamin D status.
  
  
  METHODS
  Ninety-eight subjects volunteered to receive an 80,000 IU vitamin D3 dose every month between November 2014 and April 2015. Serum 25OHD, calcemia and calciuria were measured just before the first dose (Month 0), just before the 4th dose (M4), and one month after the 6th dose (M7).
  
  
  RESULTS
  At M0, 25OHD was 17.5±9.5ng/mL. Sixty subjects (61.2%) had a 25OHD<20ng/mL and 25 (25.5%) had a 25OHD<10ng/mL. 25OHD increased significantly at M4 (35.3±8.0ng/mL) and M7 (40.1±8.5) without change in calcemia and calciuria. At M4, 2 subjects had a 25OHD slightly below 20ng/mL (17.6 and 19.7ng/mL), and none had a concentration>60ng/mL. At M7, all had a serum 25OHD>20ng/mL and 2 subjects had a value slightly above 60ng/mL (62.1 and 63.2ng/mL).
  
  
  CONCLUSIONS
  A monthly supplementation with 80,000 IU vitamin D3 between November and April corrected vitamin D insufficiency in subjects in whom it was initially very frequent, without overdosing. This protocol is simple, safe and costless, and can be easily implemented when physicians detect risk factors for hypovitaminosis D in patients for whom a 25OHD measurement is not indicated.
authors.affiliation: Centre de Saclay, commissariat à l'énergie atomique et aux énergies alternatives (CEA), service de santé au travail, 91191 Gif/Yvette cedex, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Tournier
authors.affiliation: Centre de Saclay, commissariat à l'énergie atomique et aux énergies alternatives (CEA), service de santé au travail, 91191 Gif/Yvette cedex, France.
authors.forename: Nicole
authors.initials: N
authors.lastname: Tran
authors.affiliation: Centre de Saclay, commissariat à l'énergie atomique et aux énergies alternatives (CEA), service de santé au travail, 91191 Gif/Yvette cedex, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dray
authors.affiliation: Centre de Saclay, commissariat à l'énergie atomique et aux énergies alternatives (CEA), service de santé au travail, 91191 Gif/Yvette cedex, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Brusset
authors.affiliation: Centre de Saclay, commissariat à l'énergie atomique et aux énergies alternatives (CEA), service de santé au travail, 91191 Gif/Yvette cedex, France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Rander
authors.affiliation: Centre de Saclay, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), laboratoire de biologie médicale, 91191 Gif/Yvette Cedex, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Millot
authors.affiliation: Centre de Saclay, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), laboratoire de biologie médicale, 91191 Gif/Yvette Cedex, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Bourcier
authors.affiliation: Université de Liège, CHU de Liège, service de chimie clinique, Liège, Belgium.
authors.forename: Étienne
authors.initials: É
authors.lastname: Cavalier
authors.affiliation: Assistance publique des Hôpitaux de Paris (AP-HP), hôpital Necker-Enfants-Malades, service des explorations fonctionnelles, 149, rue de Sèvres, 75015 Paris, France. Electronic address: jean-claude.souberbielle@nck.aphp.fr.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Souberbielle
mesh_terms: D000328:Adult; D000368:Aged; D002762:Cholecalciferol / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood; D014808:Vitamin D Deficiency / Q000097:blood* / Q000188:drug therapy*; D014815:Vitamins / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D014815:Vitamins; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D